Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Raw Materials (2018 - 2025)

Neurocrine Biosciences' Raw Materials history spans 8 years, with the latest figure at $31.9 million for Q1 2025.

  • For Q1 2025, Raw Materials rose 76.24% year-over-year to $31.9 million; the TTM value through Mar 2025 reached $31.9 million, up 76.24%, while the annual FY2024 figure was $33.7 million, 56.74% up from the prior year.
  • Raw Materials reached $31.9 million in Q1 2025 per NBIX's latest filing, down from $33.7 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $33.7 million in Q4 2024 to a low of $11.2 million in Q4 2021.
  • Average Raw Materials over 5 years is $21.7 million, with a median of $21.4 million recorded in 2023.
  • Peak YoY movement for Raw Materials: plummeted 32.53% in 2021, then skyrocketed 79.17% in 2023.
  • A 5-year view of Raw Materials shows it stood at $11.2 million in 2021, then grew by 7.14% to $12.0 million in 2022, then surged by 79.17% to $21.5 million in 2023, then skyrocketed by 56.74% to $33.7 million in 2024, then decreased by 5.34% to $31.9 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Raw Materials are $31.9 million (Q1 2025), $33.7 million (Q4 2024), and $23.7 million (Q3 2024).